Category: 65-71-4

On December 31, 2020, Ben Imeddourene, A.; Zargarian, L.; Buckle, M.; Hartmann, B.; Mauffret, O. published an article.Application of 65-71-4 The title of the article was Slow motions in A·T rich DNA sequence. And the article contained the following:

In free B-DNA, slow (microsecond-to-millisecond) motions that involve equilibrium between Watson-Crick (WC) and Hoogsteen (HG) base-pairing expand the DNA dynamic repertoire that could mediate DNA-protein assemblies. R1ρ relaxation dispersion NMR methods are powerful tools to capture such slow conformational exchanges in solution using 13C/15N labeled DNA. Here, these approaches were applied to a dodecamer containing a TTAAA element that was assumed to facilitate nucleosome formation. NMR data and inferred exchange parameters assign HG base pairs as the minor, transient conformers specifically observed in three successive A·T base pairs forming the TAA·TTA segment. The abundance of these HG A·T base pairs can be up to 1.2% which is high compared to what has previously been observed Data analyzes support a scenario in which the three adenines undergo non-simultaneous motions despite their spatial proximity, thus optimizing the probability of having one HG base pair in the TAA·TTA segment. Finally, revisiting previous NMR data on H2 resonance linewidths on the basis of our results promotes the idea of there being a special propensity of A·T base pairs in TAA·TTA tracts to adopt HG pairing. In summary, this study provides an example of a DNA functional element submitted to slow conformational exchange. More generally, it strengthens the importance of the role of the DNA sequence in modulating its dynamics, over a nano- to milli-second time scale. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Application of 65-71-4

The Article related to slow motion dna sequence a t protein base pair, General Biochemistry: Nucleic Acids and Their Constituents and other aspects.Application of 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On November 5, 2020, Piccinni, Viviana; Reiter, Sebastian; Keefer, Daniel; de Vivie-Riedle, Regina published an article.Synthetic Route of 65-71-4 The title of the article was Multiscale Conformational Sampling Reveals Excited-State Locality in DNA Self-Repair Mechanism. And the article contained the following:

UV irradiation is known to be responsible for DNA damage. However, exptl. studies in DNA oligonucleotides have shown that UV light can also induce sequence-specific self-repair. Following charge transfer from a guanine adenine sequence adjacent to a cyclobutane pyrimidine dimer (CPD), the covalent bond between the two thymines could be cleaved, recovering the intact base sequence. Mechanistic details promoting the self-repair remained unclear, however. In our theor. study, we investigated whether optical excitation could directly lead to a charge-transfer state, thereby initiating the repair, or whether the initial excited state remains localized on a single nucleobase. We performed conformational sampling of 200 geometries of the damaged DNA double strand solvated in water and used a hybrid quantum and mol. mechanics approach to compute excited states at the complete active space perturbation level of theory. Anal. of the conformational data set clearly revealed that the excited-state properties are uniformly distributed across the fluctuations of the nucleotide in its natural environment. From the electronic wavefunction, we learned that the electronic transitions remained predominantly local on either adenine or guanine, and no direct charge transfer occurred in the exptl. accessed energy range. The investigated base sequence is not only specific to the CPD repair mechanism but ubiquitously occurs in nucleic acids. Our results therefore give a very general insight into the charge locality of UV-excited DNA, a property that is regarded to have determining relevance in the structural consequences following absorption of UV photons. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Synthetic Route of 65-71-4

The Article related to dna cyclobutane pyrimidine dimer repair excited state uv photoexcitation, Radiation Biochemistry: Effects On Biochemical Substances and other aspects.Synthetic Route of 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 30, 2020, Li, Qian; Zhao, Jiemin; Liu, Longfei; Jonchhe, Sagun; Rizzuto, Felix J.; Mandal, Shankar; He, Huawei; Wei, Sansen; Sleiman, Hanadi F.; Mao, Hanbin; Mao, Chengde published an article.Computed Properties of 65-71-4 The title of the article was A poly(thymine)-melamine duplex for the assembly of DNA nanomaterials. And the article contained the following:

Abstract: The diversity of DNA duplex structures is limited by a binary pair of hydrogen-bonded motifs. Here we show that poly(thymine) self-associates into antiparallel, right-handed duplexes in the presence of melamine, a small mol. that presents a triplicate set of the hydrogen-bonding face of adenine. X-ray crystallog. shows that in the complex two poly(thymine) strands wrap around a helical column of melamine, which hydrogen bonds to thymine residues on two of its three faces. The mech. strength of the thymine-melamine-thymine triplet surpasses that of adenine-thymine base pairs, which enables a sensitive detection of melamine at 3 pM. The poly(thymine)-melamine duplex is orthogonal to native DNA base pairing and can undergo strand displacement without the need for overhangs. Its incorporation into two-dimensional grids and hybrid DNA-small-mol. polymers highlights the poly(thymine)-melamine duplex as an addnl. tool for DNA nanotechnol. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Computed Properties of 65-71-4

The Article related to polythymine melamine duplex dna nanomaterial, Biochemical Methods: Other (Not Covered At Other Subsections) and other aspects.Computed Properties of 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 30, 2022, Bonifacio, Lillian Gonzalez; Melo, Mirele; Ayo, Christiane Maria; Assoni, Leticia Carolina Paraboli; Olimpio, Larissa Martins; Nogueira, Mariana Reis; Spegiorin, Ligia Cosentino Junqueira Franco; Barbosa, Deusenia Machado Ulisses; de Mattos, Luiz Carlos; Pereira-Chioccola, Vera Lucia; Brandao, Cinara Cassia published an article.Formula: C5H6N2O2 The title of the article was TNFalpha rs1799964 TT genotype may be a susceptibility factor for vertical transmission of Toxoplasma gondii and clinical signs in newborns from pregnant women with acute toxoplasmosis. And the article contained the following:

One of the main impacts of Toxoplasma gondii infection occurs during pregnancy and is related to the vertical transmission of the parasite (congenital toxoplasmosis), which can cause severe clin. outcomes and fetal death. During acute infection, in order to control the rapid replication of tachyzoites, different host immune response genes are activated, and these include cytokine-encoding genes. Considering that polymorphisms in cytokine genes may increase susceptibility to vertical transmission of T. gondii by determining the immune status of the pregnant woman, this study evaluated the influence of polymorphisms of tumor necrosis factor alpha (TNFα) rs1799964 (- 1031) and interleukin 1 beta (IL1β) rs16944 (- 511) genes on gestational toxoplasmosis and on the vertical transmission of the parasite and verified the allele and genotype frequency of these polymorphisms in pregnant patients whose resp. newborn did or did not present clin. abnormalities suggestive of congenital toxoplasmosis. Methods and results: A total of 204 pregnant patients with (n = 114) or without (n = 90) infection by T. gondii were enrolled. No associations were found involving the polymorphisms rs1799964 (- 1031) of the TNFα gene and rs16944 (- 511) of the IL1β gene with the increased chance of T. gondii infection during pregnancy. However, it was observed that the maternal TT genotype referring to the polymorphism of the TNFα gene seems to influence the vertical transmission of the parasite (P = 0.01; χ2 = 6.05) and the presence of clin. manifestation in newborns from pregnancies with acute toxoplasmosis (P = 0.007; χ2 = 9.68). Conclusion: The TNFα rs1799964 TT genotype may act as a susceptibility factor for the vertical transmission of parasite and for the presence of clin. signs in newborns from pregnant women with acute toxoplasmosis. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Formula: C5H6N2O2

The Article related to toxoplasma tnfalpha genotype acute toxoplasmosis pregnancy newborn, gestational toxoplasmosis, polymorphisms, tnfα and il1β, toxoplasmosis, Mammalian Pathological Biochemistry: Obstetrics – Gynecology and other aspects.Formula: C5H6N2O2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

D’Antonio, Matteo; Nguyen, Jennifer P.; Arthur, Timothy D.; Matsui, Hiroko; Donovan, Margaret K. R.; D’Antonio-Chronowska, Agnieszka; Frazer, Kelly A. published an article in 2022, the title of the article was In heart failure reactivation of RNA-binding proteins is associated with the expression of 1,523 fetal-specific isoforms.COA of Formula: C5H6N2O2 And the article contains the following content:

Reactivation of fetal-specific genes and isoforms occurs during heart failure. However, the underlying mol. mechanisms and the extent to which the fetal program switch occurs remains unclear. Limitations hindering transcriptome-wide analyses of alternative splicing differences (i.e. isoform switching) in cardiovascular system (CVS) tissues between fetal, healthy adult and heart failure have included both cellular heterogeneity across bulk RNA-seq samples and limited availability of fetal tissue for research. To overcome these limitations, we have deconvoluted the cellular compositions of 996 RNA-seq samples representing heart failure, healthy adult (heart and arteria), and fetal-like (iPSC-derived cardiovascular progenitor cells) CVS tissues. Comparison of the expression profiles revealed that reactivation of fetal-specific RNA-binding proteins (RBPs), and the accompanied re-expression of 1,523 fetal-specific isoforms, contribute to the transcriptome differences between heart failure and healthy adult heart. Of note, isoforms for 20 different RBPs were among those that reverted in heart failure to the fetal-like expression pattern. We determined that, compared with adult-specific isoforms, fetal-specific isoforms encode proteins that tend to have more functions, are more likely to harbor RBP binding sites, have canonical sequences at their splice sites, and contain typical upstream polypyrimidine tracts. Our study suggests that compared with healthy adult, fetal cardiac tissue requires stricter transcriptional regulation, and that during heart failure reversion to this stricter transcriptional regulation occurs. Furthermore, we provide a resource of cardiac developmental stage-specific and heart failure-associated genes and isoforms, which are largely unexplored and can be exploited to investigate novel therapeutics for heart failure. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).COA of Formula: C5H6N2O2

The Article related to transcriptome mbnl1 fmr1 matr3 ipsc exoc7 heart failure adult, Mammalian Pathological Biochemistry: Cardiovascular Diseases and other aspects.COA of Formula: C5H6N2O2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 31, 2021, Yoshida, Yoichiro; Yamada, Takeshi; Kamiyama, Hirohiko; Kosugi, Chihiro; Ishibashi, Keiichiro; Yoshida, Hiroshi; Ishida, Hideyuki; Yamaguchi, Satoru; Kuramochi, Hidekazu; Fukazawa, Atsuko; Sonoda, Hiromichi; Yoshimatsu, Kazuhiko; Matsuda, Akihisa; Hasegawa, Suguru; Sakamoto, Kazuhiro; Otsuka, Toshiaki; Koda, Keiji; TAS CC3 Study Group. published an article.Reference of 5-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. And the article contained the following:

Abstract: Our study exclusively examined patients receiving this combination as a third-line treatment to investigate the clin. impact beyond cytotoxic doublets. Methods: This investigator-initiated, open-label, single-arm, multi-centered phase II study was conducted in Japan. Eligible CRC patients were refractory or intolerant to fluoropyrimidine, irinotecan, and oxaliplatin in first- and second-line therapy. TAS-102 (35 mg/m2) was given orally twice daily on days 1-5 and 8-12 in a 4-wk cycle, and bevacizumab (5 mg/kg) was administered by i.v. infusion every 2 wk. The primary endpoint was PFS and the secondary endpoints were time-to-treatment failure, response rate, overall survival (OS), and safety. Results: Between June 2016 and August 2017, 32 patients were enrolled. All patients previously received bevacizumab. The median PFS was 4.5 mo; the median overall survival was 9.3 mo. Partial response was observed in two patients. The most common adverse events above grade 3 were neutropenia followed by thrombocytopenia. There were no non-hematol. adverse events above grade 3 and no treatment-related deaths occurred. Conclusions: This study met its primary endpoint of PFS, which is comparable to the results of the C-TASK FORCE study. The TAS-102 and bevacizumab combination has the potential to be a therapeutic option for third-line treatment of metastatic CRC. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Reference of 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to metastatic colorectal cancer tas 102 bevacizumab japan, bevacizumab, chemotherapy, colorectal cancer, neutropenia, tas-102, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Reference of 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Ogata, Misato; Kotaka, Masahito; Ogata, Takatsugu; Hatachi, Yukimasa; Yasui, Hisateru; Kato, Takeshi; Tsuji, Akihito; Satake, Hironaga published an article in 2020, the title of the article was Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.COA of Formula: C5H6N2O2 And the article contains the following content:

Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic colorectal cancer patients previously treated with standard chemotherapies; therefore, we compared the efficacy and safety of these two treatments. Patients with metastatic colorectal cancer treated with REG or FTD/TPI as a salvage-line therapy from May 2014 to Dec. 2017 were included. We retrospectively analyzed long-term survival, safety, and clin. outcomes. Among 134 patients, 57 and 77 received REG and FTD/TPI, resp. The REG group received more prior systemic chemotherapies and significantly more frequent addnl. chemotherapies than the FTD/TPI group did. The median follow-up was 6.2 mo, whereas the median overall survival was 9.9 and 11.4 mo in the REG and FTD/TPI groups, resp. (hazard ratio = 0.954, p = 0.837). The median progression-free survival was 2.0 and 3.3 mo in the REG and FTD/TPI groups, resp. (hazard ratio = 0.52, p = 0.00047), indicating significant differences, whereas the objective response and disease control rates did not differ. The median overall survival of patients with addnl. subsequent chemotherapies after disease progression was longer than that of patients without addnl. chemotherapy. The most frequent grade ≥3 adverse events were hypertension and neutropenia in the REG and FTD/TPI groups, resp. Our study suggested that sequential use of both drugs may prolong survival. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).COA of Formula: C5H6N2O2

The Article related to metastatic colorectal cancer regorafenib trifluridine tipiracil chemotherapy japan, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.COA of Formula: C5H6N2O2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 31, 2020, Pfeiffer, Per; Yilmaz, Mette; Moller, Soren; Zitnjak, Daniela; Krogh, Merete; Petersen, Lone Noergaard; Poulsen, Laurids Oestergaard; Winther, Stine Braendegaard; Thomsen, Karina Gravgaard; Qvortrup, Camilla published an article.Recommanded Product: 65-71-4 The title of the article was TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. And the article contained the following:

TAS-102 (trifluridine-tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer. Inspired by the encouraging results of a small phase 1-2 study, C-TASK FORCE, which evaluated the combination of TAS-102 plus bevacizumab in patients with chemorefractory metastatic colorectal cancer, we aimed to compare the efficacy of TAS-102 plus bevacizumab vs. TAS-102 monotherapy in patients receiving refractory therapy for metastatic colorectal cancer . This investigator-initiated, open-label, randomized, phase 2 study enrolled patients (aged ≥18 years) with metastatic colorectal from four cancer centers in Denmark. The main inclusion criteria were histopathol. confirmed metastatic colorectal cancer refractory or intolerant to a fluoropyrimidine, irinotecan, oxaliplatin, and cetuximab or panitumumab (only for RAS wild-type), and WHO performance status of 0 or 1. Previous therapy with bevacizumab, aflibercept, ramucirumab, or regorafenib was allowed but not mandatory. Participants were enrolled and randomly assigned (1:1) in block sizes of two, four, or six by a web-based tool to receive oral TAS-102 (35 mg/m2 twice daily on days 1-5 and 8-12 every 28 days) alone or combined with i.v. bevacizumab (5 mg/kg on days 1 and 15) until progression, unacceptable toxicity, or patient decision to withdraw. Treatment assignment was not masked, and randomization was stratified by institution and RAS mutation status. The primary endpoint was investigator-evaluated progression-free survival. All analyses were based on intention to treat. This trial is registered with EudraCT, 2016-005241-23. From Aug 24, 2017, to Oct 31, 2018, 93 patients were enrolled and randomly assigned to TAS-102 (n = 47) or TAS-102 plus bevacizumab (n = 46). The clin. cut-off date was Feb 15, 2019, after a median follow-up of 10.0 mo (IQR 6.8-14.0). Median progression-free survival was 2.6 mo (95% CI 1.6-3.5) in the TAS-102 group vs. 4.6 mo (3.5-6.5) in the TAS-102 plus bevacizumab group (hazard ratio 0.45 [95% CI 0.29-0.72]; p = 0.0015). The most frequent grade 3 or worse adverse event was neutropenia (18 [38%] of 47 in the TAS-102 monotherapy group vs 31 [67%] of 46 in the TAS-102 plus bevacizumab group). Serious adverse events were observed in 21 (45%) patients in the TAS-102 group and 19 (41%) in the TAS-102 plus bevacizumab group. No deaths were deemed treatment related. In patients with chemorefractory metastatic colorectal cancer, TAS-102 plus bevacizumab, as compared with TAS-102 monotherapy, was associated with a significant and clin. relevant improvement in progression-free survival with tolerable toxicity. The combination of TAS-102 plus bevacizumab could be a new treatment option for patients with refractory metastatic colorectal cancer and could be a practice-changing development.Servier. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 65-71-4

The Article related to tas bevacizumab fluoropyrimidine anticancer agent colorectal cancer metastasis, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 31, 2021, Fernandez Montes, Ana; Carmona-Bayonas, Alberto; Jimenez-Fonseca, Paula; Vazquez Rivera, Francisca; Martinez Lago, Nieves; Covela Rua, Marta; Cousillas Castineiras, Antia; Gonzalez Villarroel, Paula; De la Camara Gomez, Juan; Mendez, Jose Carlos Mendez; Carriles Fernandez, Carmen; Sanchez Canovas, Manuel; Garcia Garcia, Teresa published an article.Electric Literature of 65-71-4 The title of the article was Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. And the article contained the following:

Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory anal. of the RECOURSE randomized clin. trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor burden and indolent disease. Other models in refractory mCRC are the FAS-CORRECT and Colon Life nomogram. The main objective was to externally validate the prognostic factors of the RECOURSE and FAS-CORRECT trials, and the Colon Life nomogram in a multicenter, real-world series of mCRC treated in 3rd and successive lines with trifluridine/tipiracil. The secondary aim was to develop an OS predictive model, TAS-RECOSMO. Between 2016 and 2019, 244 patients were recruited. Median OS was 8.15 vs 8.12 mo for the poor (85% of the subjects) and good (15%) prognosis groups from the RESOURCE trial, resp., log-rank p = 0.9. The most common grade 3-4 toxicities were neutropenia (17%), asthenia (6%), and anemia (5%). The AFT lognormal model TAS-RECOSMO included six variables: ECOG-PS, KRAS/NRAS/BRAF mutation status, time between diagnosis of metastasis and beginning of trifluridine/tipiracil, NLR, CEA, and alk. phosphatase. The models bootstrapped bias-corrected c-index was 0.682 (95% CI, 0.636-0.722). The factors from the Colon Life model, FAS-CORRECT, and RECOURSE displayed a c-index of 0.690, 0.630, and 0.507, resp. TAS-RECOSMO, FAS-CORRECT, and the Colon Life nomogram appear to predict OS in patients with refractory mCCR who begin trifluridine/tipiracil treatment in the real world. The prognostic groups of the RECOURCE RCT were unable to capture the situation of real-world subjects treated with trifluridine/tipiracil in this series. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Electric Literature of 65-71-4

The Article related to trifluridine tipiracil colorectal cancer survival human, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Electric Literature of 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 1, 2020, Varghese, Anna M.; Cardin, Dana B.; Hersch, Jonathan; Benson, Al B.; Hochster, Howard S.; Makris, Lukas; Hamada, Kensuke; Berlin, Jordan D.; Saltz, Leonard B. published an article.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was Phase I study of trifluridine/tipiracil plus irinotecan and bevacizumab in advanced gastrointestinal tumors. And the article contained the following:

Purpose: This two-part phase Ib trial determined the maximum tolerated dose (MTD) of the combination of trifluridine/tipiracil (FTD/TPI) and irinotecan in patients with advanced gastrointestinal tumors, and evaluated the safety, pharmacokinetics, and antitumor activity of the FTD/TPI, irinotecan, and bevacizumab triplet combination in previously treated metastatic colorectal cancer (mCRC). Patients and Methods: Dose escalation (3 + 3 design) in advanced gastrointestinal tumors was followed by expansion in mCRC. During dose escalation, patients received FTD/TPI (20-35 mg/m2 twice daily; days 1-5 of a 14-day cycle) and irinotecan (120-180 mg/m2; day 1). During expansion, the MTD of FTD/TPI and irinotecan plus bevacizumab (5 mg/kg; day 1) was administered. Results: Fifty patients (26 across six dose-escalation cohorts and 24 in the expansion phase) were enrolled. Two dose-limiting toxicities (fatigue and neutropenia) were observed in the dose-escalation phase, and MTD was defined as FTD/TPI 25 mg/m2 twice daily plus irinotecan 180 mg/m2. In the expansion phase, 83% (20/24) experienced any-cause grade ≥3 adverse events (AEs) with the triplet combination, most frequently neutropenia (42%), leukopenia (25%), and diarrhea (12%). AEs of any-cause led to dosing interruptions, modifications, and discontinuations in 29%, 17%, and 4% of patients, resp. No treatment-related deaths occurred. Three patients (12%) experienced partial responses and 16 (67%) patients had stable disease lasting >4 mo. The median progression-free survival was 7.9 mo (95% confidence interval, 5.1-13.4 mo). Conclusions: Tolerability and activity observed in this phase I trial support further investigation of the FTD/TPI-irinotecan-bevacizumab combination in previously treated mCRC. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to trifuridne tipiracil anticancer gastrointestinal tumors, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 5-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia